Skip to content
Editorial illustration for FDA approves talazoparib plus enzalutamide for metastatic pr

FDA approves talazoparib plus enzalutamide for metastatic pr

CancerSnoop News

Talazoparib prostate cancer: The FDA has approved a new combination treatment using talazoparib and enzalutamide for adults with a specific type of advanced prostate cancer.

What happened

On October 26, 2026, the U.S. Food and Drug Administration (FDA) approved talazoparib (Talzenna) together with enzalutamide to treat adults with metastatic prostate cancer that has not yet been treated with certain hormone-lowering therapies or remains sensitive to them. This approval is for patients whose cancer has specific changes in their DNA repair genes, known as homologous recombination repair (HRR) mutations, identified by approved tests.

The approval is based on a study called TALAPRO-3, where 599 patients with these HRR mutations received either talazoparib plus enzalutamide or a placebo plus enzalutamide. Patients taking the combination drug had longer periods without the cancer worsening, compared to those taking enzalutamide alone.

However, overall survival data is not yet mature. Patients must also be on ongoing hormone therapy or have had surgery to lower male hormone effects.

The FDA notes precautions due to risks of certain bone marrow problems and embryo-fetal toxicity. This new treatment represents an additional option to manage this form of prostate cancer.

Who this concerns

This information is important for adults diagnosed with metastatic prostate cancer who have HRR gene mutations and have not yet received certain hormone therapies, as well as their families and caregivers.

What the evidence shows

The approval comes from the TALAPRO-3 trial, a randomized, double-blind study showing a significant delay in cancer progression with talazoparib plus enzalutamide. The gene mutations were identified using specialized DNA tests on tumor tissue or blood samples.

The main benefit seen was longer progression-free survival compared to placebo with enzalutamide.

What remains unclear

While the study showed a clear benefit in delaying cancer progression, the data on overall survival benefit is not yet available. The safety profile requires monitoring for serious side effects related to bone marrow health, and the treatment is not suitable for patients without effective hormone therapy.

Bottom line

The FDA’s approval means some prostate cancer patients with HRR mutations now have a new treatment option combining talazoparib with enzalutamide, which can delay cancer growth more effectively than hormone therapy alone.

Official announcement

SHARE THIS EVIDENCE
WhatsApp ↗
Back To Top